Home › Learn › Tributyrin vs Sodium Butyrate: Why Delivery Decides What Reaches Your Gut

Tributyrin vs Sodium Butyrate: Why Delivery Decides What Reaches Your Gut

Published 2026-09-16 · Last reviewed 2026-09-16 · By Andy Palenzuela, Founder

Most butyrate supplements are judged by the milligrams on the front of the bottle. That is the wrong number. Butyrate is a short-chain fatty acid that the cells lining your colon use as their primary fuel — but a butyrate molecule swallowed as a salt and a butyrate molecule swallowed as a triglyceride do not behave the same way between your mouth and your intestine.

This article compares sodium butyrate and tributyrin on chemistry, delivery, and what the research actually measured. It is written by the founder of Age Revive, who spent 14+ years inside regulated nutrition supply chains watching which formulation decisions get made for the label and which get made for the gut.

Key facts

  • Butyrate: is a short-chain fatty acid produced when gut bacteria ferment fiber. It is the primary fuel for colonocytes (colon lining cells) and supports gut-barrier integrity.
  • Sodium butyrate: is butyrate as a salt. It is water-soluble, dissolves readily, and roughly a fifth of its weight is sodium.
  • Tributyrin: is three butyrate molecules bonded to a glycerol backbone — a triglyceride. It does not dissolve in water, is not released by stomach acid, and is broken apart by lipase enzymes in the intestine.
  • Enteric coating: is a separate decision from ingredient form. It keeps a capsule closed until it has left the stomach.
  • Human data: there are no published human tributyrin trials with percentage outcomes. The best-known delivery study (Miyoshi 2011) is in rats. Read claims accordingly.
  • CELLUBIOME: uses 500 mg of tributyrin per serving in an enteric-coated capsule, paired with 500 mg of urolithin A.

What butyrate is and why the gut lining cares

Butyrate is one of three main short-chain fatty acids (with acetate and propionate) that bacteria in the colon produce from fiber you cannot digest yourself. Colonocytes preferentially burn butyrate for energy. That is why it shows up in almost every serious discussion of gut-barrier integrity: the barrier is made of cells, and those cells need fuel.

Most people get their butyrate the normal way — from fermentation of fiber in the colon. A butyrate supplement is not a replacement for that. It is a way to supply butyrate directly when someone wants to support colonocyte function and barrier integrity without relying entirely on fermentation output.

The catch is that butyrate has to arrive intact, in the intestine, to do anything useful there. Which brings us to form.

Sodium butyrate: a salt that dissolves early

Sodium butyrate is what you get when butyric acid is neutralized with sodium. It is a crystalline solid, it is inexpensive, and it is the form most early butyrate supplements used.

Three things follow from it being a salt:

1. It dissolves as soon as it meets water. Salts dissociate. Sodium butyrate does not need an enzyme to release butyrate — it releases in the stomach, or in the glass, if you open the capsule. Free butyrate is then absorbed early or dealt with by the stomach and upper small intestine rather than travelling further down.

2. It carries sodium. Basic chemistry: sodium is about 21% of sodium butyrate by mass. A 1,000 mg dose brings roughly 210 mg of sodium along with it. That is not dangerous for most people, but it is an unlabeled tax on a "gut" supplement.

3. It smells. Butyric acid is the compound responsible for the odor of rancid butter and vomit. Anyone who has opened a sodium butyrate bottle knows this. The smell is not a quality defect; it is the free acid escaping. It is also the clearest evidence that the butyrate in that bottle is unprotected.

Manufacturers try to solve the early-release problem by coating sodium butyrate in fat matrices or capsules. That works to a degree, but it is a patch on the wrong molecule.

Tributyrin: three butyrates on a glycerol backbone

Tributyrin is butyrate in triglyceride form — the same structure your body uses to store and transport fats. Three butyric-acid molecules are esterified to one glycerol. The result is an oily, water-insoluble molecule that does not dissociate in the stomach the way a salt does.

To release butyrate from tributyrin, the body has to cleave the ester bonds. That job belongs to lipase enzymes, which act in the intestine, not the stomach. This is what makes tributyrin a prodrug of butyrate: an inactive carrier that the body converts into the active molecule at the point of digestion.

The practical consequences:

  • No early release from acid. Tributyrin passes through the stomach chemically intact.
  • No sodium load. There is no metal ion in the molecule.
  • Far less odor. The butyrate is bound, not free.
  • Higher butyrate density by weight. Three butyrates per molecule, minus the glycerol.

What the preclinical research measured: in a 2011 rat study, oral tributyrin raised butyrate concentrations in the portal vein — the blood vessel that carries absorbed nutrients from the intestine to the liver — within an hour of dosing (Miyoshi 2011). That is animal data showing that swallowed tributyrin is converted to butyrate and absorbed from the gut. It is not a human outcome trial, and it did not test any finished supplement.

Tributyrin vs sodium butyrate at a glance

Sodium butyrateTributyrin
Chemical formSalt (butyrate + sodium)Triglyceride (3 butyrates + glycerol)
Water solubilityHigh — dissolves readilyLow — oily, insoluble
Behavior in stomach acidDissociates; butyrate released earlyChemically stable; passes through
How butyrate is releasedDissolution (no enzyme needed)Lipase cleavage in the intestine
Sodium content~21% by massNone
OdorStrong (free butyric acid)Minimal (butyrate is bound)
Butyrate per gram~79%~87%
Preclinical delivery dataLimitedMiyoshi 2011 (rat, portal-vein butyrate)
Human outcome trialsNone establishing supplement outcomesNone establishing supplement outcomes

Neither form has human trials that let a supplement brand promise you a result. The comparison is about delivery logic, not proven outcomes.

Why CELLUBIOME uses enteric-coated tributyrin, not one or the other

Ingredient form and capsule design are two separate engineering decisions. Tributyrin solves the molecule problem: it does not fall apart in acid. Enteric coating solves the capsule problem: it keeps the contents sealed until the capsule has left the stomach.

CELLUBIOME uses both. Each serving (2 capsules) contains 500 mg of tributyrin inside a hypromellose capsule with an enteric coating (hypromellose and PEG), alongside 500 mg of urolithin A. The tributyrin is there to supply butyrate to support colonocyte function and gut-barrier integrity. The urolithin A is there for a different job — supporting mitochondrial renewal through the mitophagy pathway. Gut barrier and mitochondria, one formula. If you want the reasoning behind that pairing, it is covered in Urolithin A + Tributyrin: Gut Barrier and Mitochondrial Support.

Every lot is third-party tested for identity and potency. The current CELLUBIOME certificate (Lot 150126, an ISO/IEC 17025-accredited lab) is published on our quality page: tributyrin tested at 530.80 mg per 2 capsules against a label claim of not less than 500 mg.

What the research does not show

Honest labels require honest limits.

  • No human trial has tested tributyrin in a finished supplement and reported outcomes. Miyoshi 2011 is a rat study. Delivery logic is strong; outcome promises are not available.
  • Butyrate support is not a treatment. Supporting colonocyte function and barrier integrity is a structure/function description. It is not a claim about IBS, IBD, "leaky gut," or any other condition. If you have a gut condition, that conversation belongs with your clinician.
  • Tributyrin's advantage is chemical, not magical. It survives acid because it is a triglyceride. Sodium butyrate with a good coating can also make it past the stomach. The difference is that tributyrin does not depend on the coating to protect the molecule.
  • More milligrams is not more benefit. The 500 mg dose in CELLUBIOME is a formulation decision. It has not been compared against other doses in humans.

How to read a butyrate supplement label

Five checks, in order:

  • Which form? "Sodium butyrate," "calcium butyrate," or "tributyrin." If the label just says "butyrate," ask.
  • How much per serving — of the actual compound? 500 mg of tributyrin and 500 mg of sodium butyrate are not the same amount of butyrate, and neither is the same as "500 mg butyrate complex."
  • Is the capsule enteric-coated? Look for "enteric" or "delayed-release" on the front and a coating ingredient (hypromellose, methacrylate, or similar) in the "other ingredients" line.
  • Is there a published lot certificate? Not a badge — a document with a lab name, a lot number, and a tested value.
  • What is it paired with, and why? Butyrate supports the barrier. Ask what the formula does for the cells behind it.

Frequently asked questions

Is tributyrin better than sodium butyrate? For delivery, tributyrin has the stronger chemical argument: it is stable in stomach acid, carries no sodium, and releases butyrate through lipase in the intestine rather than dissolving early. "Better" for outcomes has not been established in human trials for either form.

Why does my sodium butyrate supplement smell so bad? Because the butyrate is free. Sodium butyrate dissociates on contact with moisture and releases butyric acid, which is the same compound behind the odor of rancid butter. Tributyrin keeps butyrate bound in a triglyceride, so the smell is minimal.

Does tributyrin need an enteric coating? The molecule itself survives acid without one. Enteric coating adds a second layer by keeping the capsule sealed until it leaves the stomach. CELLUBIOME uses both — it is a belt-and-suspenders decision, not a requirement.

How much tributyrin is in CELLUBIOME? 500 mg per serving of 2 enteric-coated capsules, paired with 500 mg of urolithin A. The current lot certificate shows tributyrin tested at 530.80 mg per serving.

Sources

  1. Miyoshi M, Sakaki H, Usami M, et al. Oral administration of tributyrin increases concentration of butyrate in the portal vein and prevents lipopolysaccharide-induced liver injury in rats. Clinical Nutrition. 2011;30(2):252–258. doi:10.1016/j.clnu.2010.09.012. PMID 21051124.
  2. Age Revive. CELLUBIOME Lot 150126 third-party certificate of analysis.

Related reading

  • Urolithin A + Tributyrin: Gut Barrier and Mitochondrial Support — Urolithin A has a human study behind it; tributyrin is a butyrate delivery choice. What Andreux 2019 measured and why CELLUBIOME is not a probiotic.
  • The Gut-Mitochondria Axis: Why Your Gut Lining and Your Cellular Engine Run on the Same Loop — Most "gut health" products describe the gut as a tube full of bacteria and stop there.
  • Urolithin A vs Probiotics: Two Different Jobs in the Gut — Probiotics address bacteria in the gut; urolithin A is a metabolite studied for its role in mitochondria. They address two different problems.
  • How to Choose a Urolithin A Supplement: The Six-Check Label Test — Six checks that separate real urolithin A supplements from precursors and trace-dose products, from studied dose and purity to price.

CELLUBIOME product page · Science · FAQ · All Learn articles

About the author

Andy Palenzuela is the founder of Age Revive and has 14+ years of experience in regulated nutrition supply chains, including manufacturing oversight, ingredient sourcing, and quality assurance for consumer health products. Age Revive formulas are developed based on published peer-reviewed research and manufactured at cGMP-certified facilities. LinkedIn

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information in this article is for educational purposes only and is not intended as medical advice. Consult your healthcare provider before starting any supplement regimen.